Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Purpose
Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)
Condition
- Liver Neoplasms
Eligibility
- Eligible Ages
- All ages
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients with confirmed diagnosis of unresectable HCC - Physician-initiated decision to treat with regorafenib (prior to study enrollment)
Exclusion Criteria
- Participation in an investigational program with interventions outside of routine clinical practice - Past treatment with regorafenib
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| uHCC patients treated with regorafenib | Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician) |
|
More Details
- Status
- Completed
- Sponsor
- Bayer